GLPwatch
Papers (10404)
Page 104 of 174, ranked by citation count.
- [New drug for type 2 diabetes: introduction of oral Semaglutide (Rybelsus<sup>®</sup> tablets), an oral GLP-1 receptor agonist].
- Semaglutide single-dose pen-injector: Post hoc analysis of summative usability testing for weight management.
- Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
- Oral versus subcutaneous semaglutide weight loss outcomes after two years among patients with type 2 diabetes in a real-world database.
- Case report: Nerve fiber regeneration in children with melanocortin 4 receptor gene mutation related obesity treated with semaglutide.
- Acute Pancreatitis Caused by Tirzepatide.
- Resolution of symptoms of binge eating disorder associated with semaglutide treatment for obesity and type 1 diabetes.
- Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy.
- Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus.
- Hearing protection and damage mitigation in Chinchillas exposed to repeated low-intensity blasts.
- Spinal cord-wide structural disruption in type 2 diabetes rescued by exenatide "a glucagon-like peptide-1 analogue" via down-regulating inflammatory, oxidative stress and apoptotic signaling pathways.
- Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis.
- Clinical effects of liraglutide are possibly influenced by hypertriglyceridemia and remaining pancreatic β-cell function in subjects with type 2 diabetes mellitus.
- Prolonged activity of exenatide: Detailed comparison of Site-specific linear polyglycerol- and poly(ethylene glycol)-conjugates.
- Non-targeted metabolomic analysis predicts the therapeutic effects of exenatide on endothelial injury in patients with type 2 diabetes.
- Characterization of glucagon-like peptide-1 (GLP-1) agonist exposures reported to a single United States poison center.
- Continuous Glucose Monitoring and the Effect of Liraglutide in Cardiac Surgery Patients: A Substudy of the Randomized Controlled GLOBE Trial.
- Semaglutide or Placebo for Nonalcoholic Steatohepatitis. Reply.
- Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.
- Short-Term Effectiveness and Reduction in Insulin Requirements in Patients With Type 2 Diabetes Treated With IdegLira in a Real-World Setting.
- Exenatide-Induced Panniculitis: Utility of the Acid-Fast Stain to Identify Injected Microspheres.
- Testicular cytoprotective effect of glucagon like peptide-1 in diabetic rats involves inhibition of apoptosis, endoplasmic reticulum stress and activation of autophagy.
- Development and validation of a rapid high-performance liquid chromatography method for the quantification of exenatide.
- Severe Hypomagnesemia and Hypocalcemia Linked to Semaglutide in Type 2 Diabetes: A Case Report.
- Semaglutide Mitigates Ischemic Brain Injury by Inhibiting Ferroptosis via Modulation of FoXO1 and DRP1 Pathways.
- Liraglutide in heart failure: caution is needed.
- Clinical effectiveness of exenatide in diabetic patients waiting for bariatric surgery.
- Liraglutide improves sevoflurane-induced postoperative cognitive dysfunction via activating autophagy and inhibiting apoptosis.
- Simultaneous analysis of antihyperglycemic small molecule drugs and peptide drugs by means of dual liquid chromatography high-resolution mass spectrometry.
- Mitigation of Hearing Damage With Liraglutide Treatment in Chinchillas After Repeated Blast Exposures at Mild-TBI.
- Brain activity associated with breakthrough food preoccupation in an individual on tirzepatide.
- Treating bile acid diarrhoea with liraglutide.
- As Few as Three Months of Preoperative Semaglutide Exposure Prior to Total Knee Arthroplasty Is Associated With Reduced Postoperative Adverse Events in Patients Who Have Type II Diabetes.
- Liraglutide toxicity presenting to the emergency department: A case report and literature review.
- Meta-Analysis Assessing the Cardiovascular Safety of Semaglutide for the Treatment of Overweight or Obesity.
- Liraglutide-associated depression in a patient with type 2 diabetes: A case report and discussion.
- Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration.
- Incretin attenuates diabetes-induced damage in rat cardiac tissue.
- A novel therapeutic prospect: a dual-acting tirzepatide for Alzheimer's disease.
- Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database.
- Liraglutide intervention improves high-glucose-induced reactive gliosis of Müller cells and ECM dysregulation.
- Semaglutide in NASH-related cirrhosis: too late to the party?
- Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial.
- GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians.
- Glucagon-Like Peptide-1 Receptor Agonists-How Safe Are They?
- Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis.
- GLP-1R agonist therapy and vaccine response: Neglected implications.
- Modeling potential cost-effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity.
- Predictive factors associated with primary failure to exenatide and non goal attainment in patients with type 2 diabetes.
- Early clinical studies with liraglutide.
- Glucagon and exenatide improve contractile recovery following ischaemia/reperfusion in the isolated perfused rat heart.
- Neuroprotective effects of semaglutide and metformin against rotenone-induced neurobehavioral changes in male diabetic rats.
- Obesity Epidemic: Pharmaceutical Weight Loss.
- Assessment of Exenatide loaded Biotinylated Trimethylated Chitosan/HP- 55 Nanoparticles.
- Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans.
- Plastic surgery amid a semaglutide epidemic: Direction for future studies and service implications.
- GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction.
- Semaglutide (Wegovy) for the Treatment of Obesity.
- A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes.
- A LEAN treatment for non-alcoholic steatohepatitis.